Delving into the Latest Updates on SanQi LongXueJie Capsule with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

SanQi LongXieJie Capsule

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Cardiovascular Diseases

Inactive Indication-

Originator Organization

Dihon Pharmaceutical Group Co., Ltd.

Active Organization

Yunnan Shengke Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

China (24 Oct 2019),

Cardiovascular Diseases

Regulation-

Login to view timeline

以用药后不良事件发生率等为评价指标，评价三七龙血竭胶囊治疗冠心病稳定型劳力性心绞痛（I、II 级）的临床安全性。同时以用药结束时西雅图心绞痛调查量表（SAQ）评分较用药前的变化为主要评价指标，评价三七龙血竭胶囊治疗冠心病稳定型劳力性心绞痛（I、II 级）的临床有效性。

[Translation]

The clinical safety of Sanqi Longxuejie Capsule in the treatment of stable exertional angina pectoris (grade I and II) of coronary heart disease was evaluated by taking the incidence of adverse events after medication as the evaluation index. At the same time, the clinical effectiveness of Sanqi Longxuejie Capsule in the treatment of stable exertional angina pectoris (grade I and II) of coronary heart disease was evaluated by taking the change of Seattle Angina Questionnaire (SAQ) score at the end of medication compared with that before medication as the main evaluation index.

Start Date28 Jun 2022

Sponsor / Collaborator

Dihon Pharmaceutical Group Co., Ltd.

100 Clinical Results associated with SanQi LongXueJie Capsule

Login to view more data

100 Translational Medicine associated with SanQi LongXueJie Capsule

Login to view more data

100 Patents (Medical) associated with SanQi LongXueJie Capsule

Login to view more data

100 Deals associated with SanQi LongXueJie Capsule

Login to view more data